SK Bioscience Co Ltd

SK Bioscience's capital structure shows a debt-to-equity ratio of 0.26, indicating a relatively conservative leverage position. However, the company's liquidity is assessed as medium, with a current ratio of 3.82, suggesting it has sufficient short-term assets to cover its liabilities, but with room for improvement in cash flow management. The company's free cash flow is negative at -225.5 billion KRW, driven by a capital expenditure of -260.4 billion KRW, which reflects ongoing investment in its operations.

Profitability metrics show a return on equity of -3.21% and a return on assets of -1.94%, both significantly below the industry median for pharmaceutical companies, which typically report positive returns. The company's operating income is negative at -123.4 billion KRW, and its net income is also negative at -57.4 billion KRW, indicating a challenging financial performance in the most recent reporting period.

Geographically, SK Bioscience's revenue is primarily concentrated in South Korea, with limited exposure to international markets. The company's revenue concentration in a single market increases its vulnerability to domestic economic and regulatory changes. The company's business is segmented into vaccines and biologics, with vaccines being the primary revenue driver.

The company's growth trajectory is mixed. While it has a revenue of 651.4 billion KRW, the outlook for the current fiscal year is uncertain due to the negative operating and net income figures. The company's capital expenditure suggests a commitment to long-term growth, but the negative free cash flow indicates that this growth is currently being funded through operational cash flow rather than surplus cash.

Risk factors include the company's negative net cash position after subtracting total debt, which could limit its financial flexibility. The dilution risk is assessed as low, with no significant dilution expected in the near term. However, the company's negative returns and liquidity challenges could impact its ability to meet long-term obligations and invest in new opportunities.

Recent events include the company's ongoing efforts to expand its vaccine portfolio and secure international regulatory approvals. The company has also been involved in partnerships and collaborations to enhance its R&D capabilities and market reach. Analysts have provided a range of price targets, with a mean of 37,250 KRW and a median of 38,000 KRW, but no strong buy recommendations have been issued.